Antonio Bertoletti

Therapeutic vaccination and novel strategies to treat chronic HBV infection.

Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans.

Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody.

HBV-Specific Adaptive Immunity.

Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells.

Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases.

IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease.

Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus.

Reduction of HBV replication prolongs the early immunological response to IFNα therapy.

Immunoprevalence and immunodominance of HLA-Cw*0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region.

Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.

Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.

Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.

Cancer immunotherapy: targeting the difference.

Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.

Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation.

Hepatitis B: future curative strategies.

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.

Reply to: "To target or not to target viral antigens in HBV related HCC?".

Virus-specific T lymphocytes home to the skin during natural dengue infection.

Trained immunity in newborn infants of HBV-infected mothers.

Overview of the special issue on HBV immunity.

Understanding the T cell immune response in SARS coronavirus infection.

Immune Response in Hepatitis B Virus Infection.

Advances in therapeutics for chronic hepatitis B.

T cell fitness in the liver: How can T cells keep it up?

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.

Adaptive immunity in HBV infection.

Microfluidic models for adoptive cell-mediated cancer immunotherapies.

Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation.

Advanced Design of Dumbbell-shaped Genetic Minimal Vectors Improves Non-coding and Coding RNA Expression.

HBV in 2016: Global and immunotherapeutic insights into hepatitis B.

An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers.

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.

A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors.

T-cell therapy for chronic viral hepatitis.

Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future.

CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8 T cells to Tc1 phenotype.

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.

Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure.

Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.

Use of Expression Profiles of HBV DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.